Senior Account Executive

Axios names UCB a winner of the Metro Atlanta Top Workplaces 2026 award. Aug 16, 2026, 8:05 AM ET Recognition reflects employee feedback and comes as UCB expands its Georgia footprint through a $2 billion investment in a new biomanufacturing campus expected to create more than 330 jobs. ATLANTA, Aug. 16, 2026 /PRNewswire/ - UCB, a global biopharmaceutical company with its U.S. headquarters in metro Atlanta, has been named a winner of the 2026 Metro Atlanta Top Workplaces Award by Axios. As UCB expands its presence in Georgia, the Top Workplaces award reinforces the company's long-term investment in the state, its growing life sciences offering, and its overall culture that attracts, develops, and retains the talent needed to support innovation and a reliable medicine supply for U.S. patients. UCB has maintained its U.S. headquarters in metro Atlanta for more than 30 years and employs more than 400 people in Georgia. Earlier this year, UCB announced a $2 billion investment in a new biomanufacturing campus in Gwinnett County expected to create an additional 330+ permanent, highly-skilled jobs and generate an estimated $5 billion in economic impact. "This recognition is especially meaningful because it reflects the voices and experiences of our people," said Taco van Tiel, Head of UCB, U.S. "As UCB continues to invest in Georgia, including through our planned U.S. biologics manufacturing site, our ability to attract and support top talent will be central to delivering on our purpose for patients. We are proud to be part of the metro Atlanta community and to continue building a workplace where employees feel empowered to contribute, grow, and make an impact." EMPLOYEE FEEDBACK DRIVES TOP WORKPLACE RECOGNITION Awarded to fewer than 60 organizations with 159-499 employees across metro Atlanta, the recognition is based solely on employee feedback collected through a confidential third-party survey administered by Energage. UCB was previously a recipient of this award in 2021. "Creating an environment where talented people can do their best work is fundamental to our success at UCB. This recognition reflects the culture our employees have helped build, one rooted in collaboration, growth, and a shared commitment to improving the lives of people living with severe diseases," said Michele Ehler, Head of U.S. Talent, UCB, "We always strive to create a workplace where employees feel valued and empowered to make a difference, and we remain focused on investing in them as we grow and advance our mission in the years ahead." UCB remains focused on creating an environment where employees can thrive, develop their careers, and contribute to meaningful work. By continuing to invest in its people and culture, UCB is building the foundation needed to support future growth and deliver its commitment to patients. UCB'S GROWING PRESENCE IN GEORGIA Georgia plays a central role in UCB's long-term growth strategy in the United States. In addition to serving as the home of the company's U.S. headquarters, the state will become home to UCB's first U.S. biomanufacturing campus. FOR FURTHER INFORMATION: U.S. Communications Erica Puntel T 404.938.5359 email [email protected] About UCB in the U.S. UCB has maintained a significant U.S. presence for decades, including its U.S. headquarters and eight offices across six communities in California, Georgia, Massachusetts, North Carolina, Washington, and Washington, D.C. With nearly 2,000 U.S. employees focused on research, development, and commercial operations across the country, UCB is adding a U.S. biomanufacturing campus in Georgia, which will create 330+ new, highly skilled jobs. UCB has increased its U.S. workforce by more than 70% since 2017, with over 25% of U.S. employees dedicated to R&D. Over the last decade, UCB has made significant investments in U.S. companies through acquisitions and partnerships and has achieved 15 FDA approvals, advancing innovation, supporting high-quality jobs, and delivering meaningful progress for patients. About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB). Forward looking statements This document contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document. Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of UCB's information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in laws and/or rules pertaining to tax and duties or the administration of such laws and/or rules, and hiring, retention and compliance of employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems. Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB. UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations. SOURCE UCB NOTE: This content is not written by or endorsed by "WOWK", its advertisers, or Nexstar Media Inc.

Addressing care gaps across the patient journey: insights from the 2026 UCB Startup Program Pitch Day. Kevin Grund, Business Capability 11-Aug-2026 For people living with chronic conditions and rare diseases, better outcomes depend on improving the entire care journey, not just the care that takes place during clinical appointments. Every stage of that journey presents opportunities to improve care, from earlier diagnosis and more effective referral pathways to better-informed treatment decisions and ongoing disease management. To address key challenges across the patient journey, UCB Germany leveraged the Startup Program, one of the mechanisms established by UCB's Digital Care Transformation (DCTx) team in 2022. The program brings UCB teams together to define healthcare and business challenges aligned with local market priorities before identifying and exploring digital health solutions that can address those needs. Through close collaboration with UCB teams, participating companies contribute their expertise while benefiting from clinical, commercial, and market perspectives to evaluate real-world applications, generate actionable insights, and identify opportunities to improve patient outcomes. This year's program focused on three priority areas identified by UCB Germany: axial spondyloarthritis (axSpA), myasthenia gravis (MG), and osteoporosis. Over 14 weeks, four companies worked with UCB stakeholders to explore how digital tools could support earlier identification, improve referral, inform treatment decisions, and strengthen patient engagement. "The startups in this year's program are asking the same questions we ask ourselves at UCB. These aren't abstract innovation questions, they're the everyday realities of patients, and that's why we're working together to find practical solutions" - Pasquale Impesi, SVP Head of Europe, UCB Showcasing the 2026 cohort: Supporting earlier identification and diagnosis. Axial spondyloarthritis is often associated with significant diagnostic delays. For example, in Germany the delay from back-pain onset to axSpA diagnosis is almost 6 years. Symptoms are often non-specific and patients frequently visit multiple care providers before reaching a rheumatologist, delaying access to appropriate treatment and support. Through the Startup Program, UCB collaborated with MPIRIQ to explore how AI-supported patient identification and referral could help mitigate this issue. Working alongside clinicians and UCB experts, MPIRIQ analysed routine GP records to identify patients with suspected axSpA, supported rheumatologist validation of flagged cases, and evaluated an AI-enabled referral pathway to specialist care. Several patients flagged in the pilot had recorded clinical signs linked to inflammatory back pain, elevated inflammatory markers, or relevant testing history, but had not received a formal diagnosis. Initial rheumatologist review confirmed strong agreement with the AI-supported screening approach, demonstrating that routinely collected primary care data can help uncover overlooked patients and support earlier, more targeted referral into rheumatology care. Rethinking osteoporosis care, from detection to treatment. Vertebral compression fractures are among the strongest predictors of future osteoporotic fractures. Yet, many remain undetected on routine scans and as a result patients at highest risk may not be assessed or connected to timely treatment. These highest-risk patients, who gain most from early guideline-directed therapy, are hiding in plain sight on scans already performed. UCB partnered with ImageBiopsy Lab to turn that opportunity into a working methodology, built on ImageBiopsy Lab's, IB Lab FLAMINGO AI platform, originally a UCB initiative that opportunistically detects vertebral fractures on routine CT scans and is already validated across European health systems. Together, the teams designed and validated a downstream care pathway to support osteoporosis assessment and treatment for patients identified through IB Lab FLAMINGO, addressing the lack of established post-detection services in routine care. By closing gaps in both patient identification and treatment initiation, IB Lab FLAMINGO surfaces vertebra fractures, while the IB Lab Bridge is a tele-osteology platform that turns IB Lab FLAMINGO detection into a guideline-based, treatment-ready plan, supporting patients to receive the appropriate treatment. This approach could bring up to 35 times more high-risk patients into treatment than usual care, nearly double what detection alone achieves, lifting Germany's potential reach toward roughly 585,000 patients a year from about 16,500 today. Because prevention costs less than the fractures it averts, the pathway is built to be reimbursed through existing healthcare funding, creating a sustainable route from incidental CT scans to guideline-directed treatment. Supporting treatment decisions. For people living with myasthenia gravis (MG), treatment decisions are often made in the context of a highly variable disease course, where symptoms and daily disease burden fluctuate considerably. Yet because specialist visits typically take place only every few months, meaningful changes between appointments can go unseen, and in a condition where muscle weakness can deteriorate quickly, that lack of visibility makes timely, well-informed treatment decisions harder. To help close this gap, UCB collaborated with RareLink to explore whether continuous remote patient monitoring could form the foundation of a future patient support model. RareLink's certified platform combines patient-reported outcomes and connected devices to give treating physicians a clearer, more continuous picture of disease activity between visits. Working alongside neuromuscular specialists, the project mapped therapy-specific care gaps in MG and identified where digital monitoring could add the most value. This included earlier recognition of deterioration and better-informed treatment and dose optimization, to more structured symptom monitoring and follow-up. The greatest benefit is expected for the most unstable and hardest-to-reach patients. Together, these insights give UCB an evidence-based starting point for building remote monitoring into MG care within the German healthcare system. Bringing the patient perspective into care. Also related to MG, UCB partnered with mama health to strengthen patient support and measure patient empowerment. The mama health's patient companion app supports patients across their entire disease journey - through education, community insights, and continuous guidance - and during this project, the team made significant improvements to its AI capabilities and core features while putting patient needs first. Additionally, mama health and UCB developed a Patient Empowerment Index measuring patient awareness, engagement, and activation. One of the project's most notable findings was that patient engagement and activation lagged behind awareness. This highlights a gap between understanding and action, pointing to the value of tools that accompany patients not only at key clinical moments but at every stage of their journey. Beyond Pitch Day. The projects presented at Pitch Day on 13 July 2026, held in Monheim, Germany, and online, showcased how the Startup Program has evolved from a startup-focused initiative into model focused on addressing specific healthcare and business challenges, enabling more relevant collaborations between startups, UCB, and the wider healthcare ecosystem. By focusing on priorities identified by the local markets and working closely with external innovators, UCB teams assessed potential solutions, generated new insights, and had a better understanding of opportunities across axSpA, osteoporosis, and myasthenia gravis. Each collaboration addressed different challenges, yet collectively they demonstrate how targeted partnerships can accelerate learning, inform future priorities, and support UCB's broader goal of improving patient outcomes. Building on the insights gained from this year's cohort, DCTx will continue working with local markets to pinpoint priority challenges and explore how external innovation can help address unmet needs across various disease areas and healthcare settings.

Manufacturing Jobs Flock to the U.S. Thanks to President Trump's America First Economic Agenda Aug 4, 2026 | 2:48 PM FOR IMMEDIATE RELEASE 08/04/26 | | Manufacturing Jobs Flock to the U.S. Thanks to President Trump's America First Economic Agenda | | With President Trump's economic agenda taking effect, the United States is seeing an economic revival across its manufacturing industry. July saw the strongest expansion in domestic manufacturing activity in more than four years, marking seven consecutive months of growth in the sector. The results are clear: President Trump's Working Families Tax Cuts and America First trade policies are driving an economic boom, bringing jobs and critical industry back home. Just this week, Switzerland-based medicine maker Octapharma announced a $1.5 billion investment to build its first-ever U.S. production facility, creating 1,500 jobs. This is just the latest in a long line of foreign investments in U.S. manufacturing: * Swiss pharmaceutical company Novartis announced a $23 billion investment in 10 different U.S. manufacturing and research & development facilities, creating 4,000 jobs. * Swiss healthcare company Roche announced a $50 billion investment in U.S. manufacturing and R&D, creating more than 12,000 jobs. * Belgium-based pharmaceutical company UCB announced a $2 billion investment to build its first-ever U.S. manufacturing facility, creating over 800 jobs. * Japanese automaker Toyota announced a $3.6 billion investment to support truck production, creating 2,000 jobs. * Mexico-based aluminum recycler Zerluma announced a $50 million investment in a new U.S. manufacturing plant, creating 70 jobs. * Taiwanese chipmaker TSMC announced a $265 billion investment in U.S. manufacturing, creating tens of thousands of jobs. * Taiwanese electronics manufacturer Wistron, in partnership with NVIDIA, announced a $700 million investment in AI manufacturing, creating up to 1,000 jobs. * German engineering company Siemens announced a $165 million investment in U.S. manufacturing, creating more than 350 jobs. President Trump and his entire Administration will continue driving this revival further, making good on the promise to reshore American jobs, revitalize its domestic supply chain, and put America First. | | ### Topical Fruit